Nafamostat is a synthetic serine protease inhibitor and an anticoagulant used in haemodialysis. It induces apoptosis by upregulating TNFR1 expression, inhibits NF-kappaB activity by blocking IkappaBalpha phosphorylation, and can also inhibit SARS-CoV-2 and COVID-19.
